In the FLAURA study that comparing the efficacy of osimertinib and first-generation EGFR-TKIs in the first-line setting of advanced EGFR-mutated NSCLC, osimertinib showed improvement in both the median PFS (18.9 vs. 10.2 months, P < 0.001) [4] and the OS (38.6 vs. 31.8 months, P = 0.046) [24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.